IFNγ has an essential effect on macrophage activation and clearly a pathogenic role in MAS considering that Emapalumab, which is an anti-IFNγ monoclonal antibody, has been recently approved for the treatment of hemophagocytic lymphohistiocytosis [47–49]. Here, IFNG is linked to macrophage activation syndrome.